SKY-LABS
Attracting USD 20 million investment, Sky Labs (CEO: Jack Lee), a global health care start-up, finalized Series B Round successfully. The accumulated amount of investment Sky Labs has attracted is USD 30 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005004/en/
In addition to returning investors such as Atinum Investment, Moru Asset Management and Soo Investment Capital, new investors such as KB Investment, Korea Investment Partners and LB Investment participated this time. It is noticeable that big investors managing more than KRW 1 trillion in Korea participated in the investment. Sky Labs explains that such a great achievement was possible because the technological competitiveness and business capacity of the company were highly recognized.
Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform, which attracted attention in the healthcare market. CART-I consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platform to have AI detect and analyze atrial fibrillation and the result is delivered to the user’s application and medical professional’s web. CART-I earned CE-MDD (Medical Devices Directive) and is being prepared for U.S FDA approval.
Sky Labs has expanded its business in overseas markets since the beginning of this year. In January, CART-I was selected for clinical research to monitor atrial fibrillation led by professor Timothy Betts, a cardiologist at Oxford University Hospital. In April, Sky Labs signed a contract with Titan Commerce Continental Services GmbH, the largest wearable medical device distributor in Germany, to sell CART-I in Europe. It is ready for on/offline sales to hospitals and medical institutions in Germany, Austria and Switzerland.
Encouraged by the attracted investment, Sky Labs plans to expand global clinical research with the UK, the Netherlands, Germany and the U.S and strengthen the marketing activities of the U.S and European branches to take over global healthcare markets. In addition, it expects to develop monitoring devices for various chronic diseases, acquire approval for the devices and recruit manpower.
Kim Jinyong (M.D., Ph.D.), director of KB Investment which participated in Series B investment, said, “Analyzing heart rhythm precisely, conducting continuous monitoring of vital signs such as blood pressure and oxygen saturation and carrying out the medical analysis of the signs, CART-I is the most advanced wearable medical device. Continuous and precise monitoring outside a hospital for the constant care of chronic disease patients is an important element of tailor-made medical care. CART-I will realize it.”
Jack Lee, CEO of Sky Labs, said, “The investment we attracted this time verifies the technological and clinical capacity of our AI, software and hardware, the potential and expandability of CART platform and the high praise of our globally expanding business capacity. Accelerating the growth, we are going to bring fundamental changes to the healthcare market for chronic disease patients outside a hospital.”
Winning the Digital Health & Technology Competition of the European Society of Cardiology in 2018 and 2019 and selected as the Technology Pioneer of the World Economic Forum 2019, Sky Labs is highly recognized for its technology and competitiveness.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom